Neogen Corporation Q3 2026 Earnings Call Summary

Moby Intelligence

Thu, April 9, 2026 astatine 11:47 AM CDT 3 min read

• Food Safety conception achieved 4% halfway growth, reaching market-level show done improved commercialized rigor and request for indicator investigating and civilization media.

• Adjusted EBITDA margins expanded to 22.8% owed to disciplined outgo power and a 9% sequential simplification successful adjusted operating expenses.

• Animal Safety gross declined 8.7% connected a halfway basis, chiefly driven by third-party supplier transitions, earthy worldly shortages, and documentation issues alternatively than underlying request weakness.

• Management is transitioning the commercialized exemplary from siloed determination operations to a unified, solutions-based planetary selling model to amended leverage the afloat merchandise portfolio.

• Operational ratio efforts are focused connected centralizing the proviso concatenation and implementing AI-enabled logistics to trim the existent precocious reliance connected manual processes and labour costs.

• The institution is reallocating resources by shifting to organisation partners successful lower-impact markets to money maturation successful high-priority geographic and lawsuit segments.

• The Petrifilm manufacturing modulation remains connected docket for November 2026, with 100% of accumulation instrumentality validated and SKU validation presently underway.

• Management expects important escaped currency travel betterment successful fiscal 2027 arsenic superior expenditures for Petrifilm facilities subside and duplicative manufacturing costs are eliminated.

• Guidance for Q4 assumes a modulation from currency tailwinds to headwinds and a measured betterment timeline for Animal Safety proviso concatenation challenges.

• Strategic R&D concern successful a research-scale Petrifilm enactment is intended to accelerate introduction into caller markets specified arsenic pharmaceuticals and cosmetics by enabling customized SKU prototyping.

• The divestiture of the genomics business, expected to adjacent successful Q2 fiscal 2027, is positioned to trim nett indebtedness to adjusted EBITDA beneath 3x by the extremity of calendar 2026.

• Global logistics disruptions, peculiarly adjacent the Suez Canal, are driving precocious single-digit to debased double-digit increases successful freight and proscription costs.

• A prime contented astatine a third-party supplier for illustration postulation products led to higher scrap rates and antagonistic gross margins for that class this quarter.

• Approximately 56% of operating expenses are presently tied to salaries and benefits, which absorption attributes to humanities underinvestment successful automation.

• Animal Safety headwinds see a planetary vitamin A shortage and accumulation transitions by cardinal partners successful instruments and sodium bicarb.